Key Highlights

● GeneDx shares closed at $75.79 on Tuesday, September 29, down 11.80% from the prior close of $85.93.

● GeneDx reported second-quarter Revenue of $114.4 million, up 11%, and reaffirmed full-year revenue guidance of $475 million to $490 million.

● A sponsored program launched September 9 offers free genome sequencing for children with suspected Niemann-Pick disease type C.

● Exome and genome test Volume reached 30,785 in the second quarter, up 32% year over year.

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) fell 11.80% on Tuesday, September 29, 2026, to close at $75.79, against a prior close of $85.93. The genetic testing company was among the steeper decliners in the US market on a session when the Dow Jones Industrial Average fell 0.26% to 51,349.92. The shares have traded between $32.21 and $170.87 over the past 52 weeks.

What GeneDx Does

GeneDx provides genetic testing centered on exome and genome sequencing, which reads a patient's DNA to look for variants linked to rare and inherited conditions. The company sells its tests to clinicians and health systems, and much of its work is in pediatric and rare-disease diagnosis, where a genetic result can end a long search for an explanation of a child's symptoms.

Second-Quarter Results and Guidance

GeneDx reported second-quarter 2026 results on August 3. Revenue was $114.4 million, up 11% from a year earlier, with exome and genome revenue of $100.3 million, up 17%. Exome and genome volume reached 30,785 tests, a 32% increase. Adjusted gross Margin was 70%, adjusted Net Income was $0.4 million and the GAAP net loss was $17.7 million.

Management reaffirmed 2026 guidance for revenue of $475 million to $490 million, exome and genome volume growth of at least 30%, adjusted gross margin of about 70% and positive adjusted net income. Chief Executive Officer Katherine Stueland said the company had successfully navigated its return to profitability while managing the transition to genome testing.

Program Launches and Clinical Studies

On September 9, GeneDx and Beren Therapeutics launched NPC GenomeComplete, a sponsored program that provides free genome sequencing and targeted NPC1 and NPC2 variant testing for pediatric patients with clinical findings, family history or biomarker evidence suggestive of Niemann-Pick disease type C. Results can be returned in as little as 48 hours for eligible cases, and the testing does not require insurance. In August, the company also announced a study supporting hospital-wide adoption of rapid genomic sequencing at Seattle Children's.

Financing and the Market Backdrop

GeneDx held $133.5 million in cash as of June 30, 2026. On August 3, it agreed a financing with Blackstone that includes an additional $50 million term Loan and a $5 million Equity Investment at $61 per share, bringing pro forma cash to roughly $188 million.

The wider market offered little support on Tuesday. The 10-year Treasury Yield ended near 5.25%, and the Conference Board's consumer confidence index fell to 81.9 in September from 88.6 in August. Higher yields raise the rate used to discount long-dated earnings, which matters for a company that only recently returned to adjusted profitability.

A Wide Trading Range Ahead of October Results

The October 27 report will show whether exome and genome volume is tracking the guided growth of at least 30%. Tuesday's close left the shares about 56% below the top of the 52-week range of $170.87 and more than double the low of $32.21.